Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026

Pyxis Oncology, Inc.

Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.
Cash and equivalents $42.5M; expected runway into Q4 2026.
MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC (dose cap patients) on track for mid-2026.
MICVO + pembrolizumab Phase 1/2 combination dose escalation data in 1L R/M HNSCC expected 2H 2026.
Appointed Nelson Azoulay as Chief Business Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222818

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.